Keywords: Novo Nordisk, New indications, Children, Levemir, Victoza

EU OKs two new indications for Novo Nordisk’s Levemir

Article | 03 November 2011

Print This

There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission approved the extended ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in